You are here

Regeneron

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Biopharma Dive

Ichnos Sciences

bispecific antibodies

Flag link:

Pfizer posts detailed phase 3 data on its Dupixent rival

Pfizer posts detailed phase 3 data on its Dupixent rival

Fierce Biotech

clinical trials

atopic dermatitis

Flag link:

Eylea casts a shadow over Novartis' latest approval

Eylea casts a shadow over Novartis' latest approval

Biopharma Dive

wet age-related macular degeneration

Flag link:

Novartis backs brolucizumab with new head-to-head Eylea trial

Novartis backs brolucizumab with new head-to-head Eylea trial

Pharmaforum

clinical trials

age-related macular degeneration

Flag link:

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Fierce Pharma

PCSK9 inhibitors

Flag link:

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Fierce Pharma

Medicines Company

PCSK9 inhibitors

Flag link:

What happened a year ago this week in biopharma? August 12-18, 2018

Vertex Pharmaceuticals

cystic fibrosis

Bristol-Myers Squibb

Flag link:

What happened a year ago this week in biopharma? August 12-18, 2018

What happened a year ago this week in biopharma? August 12-18, 2018

CP WIre

Vertex Pharmaceuticals

cystic fibrosis

Bristol-Myers Squibb

Flag link:

Regeneron plots $800M New York production push—along with 1,500 new jobs

Regeneron plots $800M New York production push—along with 1,500 new jobs

Fierce Pharma

drug manufacturing

Flag link:

Regeneron drug proves effective in genetic form of high cholesterol

Regeneron drug proves effective in genetic form of high cholesterol

Stat

Homozygous Familial Hypercholesterolemia

Flag link:

Regeneron gets FDA approval for Eylea injection prefilled syringe

Regeneron gets FDA approval for Eylea injection prefilled syringe

Ophthalmology Times

Flag link:

Regeneron's Ebola treatment proves superior to rival in trial

Regeneron's Ebola treatment proves superior to rival in trial

Yahoo/Reuters

Mapp Biopharmaceutical

Flag link:

Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

BioPharma Dive

Flag link:

These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

Investors Business Daily

Bristol-Myers Squibb

Gilead Sciences

Flag link:

German court blocks sale of Sanofi, Regeneron cholesterol drug

German court blocks sale of Sanofi, Regeneron cholesterol drug

Biopharma Dive

Flag link:

Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps

Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps

Fierce Pharma

Flag link:

FDA Action Alert: Regeneron, Sanofi, Celgene

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

Flag link:

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Stat

monoclonal antibodies

Flag link:

Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?

Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?

Forbes

The Medicines Company

PCSK9 inhibitors

Flag link:

Pages